Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 89fludarabine phosphate 77Mycophenolic Acid 53Tacrolimus 52Peripheral Blood Stem Cell Transplantation 50Busulfan 44Whole-Body Irradiation 43Antilymphocyte Serum 41fludarabine 37Cyclosporine 36Filgrastim 32Melphalan 27Methotrexate 26Radiotherapy 23Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Granulocyte Colony-Stimulating Factor 16Sirolimus 14Etoposide 13Alemtuzumab 12thymoglobulin 11sargramostim 11Stem Cell Transplantation 11Rituximab 11Thiotepa 9Azacitidine 8Cytarabine 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × gilteritinib × Plasma cell × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡